ButSpeak.com
News which Matters.
New gene therapy targeting brain signaling shows promise in treating alcohol addiction, offering hope for millions struggling with AUD.
Each year, alcohol addiction devastates countless families, shattering lives and leaving millions in its wake. In the ongoing search for a solution, a new ray of hope emerges as scientists may be on the brink of a groundbreaking cure for this pervasive ailment.
A new experimental therapy for alcohol use disorder (AUD) has shown impressive results in trials with monkeys. If these results can be replicated in humans, we could be witnessing a turning point in the fight against AUD.
Renowned neuroscientists and physiologists from various US institutes have tested a pioneering gene therapy aimed at modifying core brain circuitry linked to prolonged heavy alcohol consumption. Their findings, published in the journal Nature Medicine, highlight the potential of this innovative approach.
One of the biggest challenges with AUD is relapse. Many individuals, even after concerted efforts to abstain, find themselves drawn back to alcohol. This relapse is often driven by changes in the brain’s communication network, particularly in mesolimbic dopamine (DA) signaling, which orchestrates how dopamine, the “feel-good” neurotransmitter, is transmitted.
Central to this system is a protein named glial-derived neurotrophic factor (GDNF). Research has shown that GDNF levels drop significantly in AUD patients during alcohol abstinence, especially in the ventral tegmental area (VTA) of the brain. Replenishing GDNF levels in the VTA using gene therapy could potentially fortify this vital dopaminergic signaling and prevent relapses.
Dr. Kathleen Grant, a senior co-author of the study, explained that the perception of those addicted to alcohol deriving pleasure from each drink is a misconception. While moderate drinking triggers dopamine release, chronic consumption desensitizes the brain, leading to reduced dopamine release over time. For those struggling with addiction, drinking becomes a way to alleviate the discomfort of sobriety rather than seeking pleasure.
In their study, Dr. Grant and her team conducted an experiment on eight rhesus macaque monkeys. These primates were subjected to increasing alcohol concentrations over sequential 30-day periods. Following this, the monkeys had free access to alcohol and water for 21 hours daily over six months, leading to heavy drinking tendencies.
During a 12-week abstinence phase, half the monkeys received GDNF gene therapy delivered directly into their VTA using a viral vector carrying a copy of the human GDNF gene. The results were staggering, with treated monkeys almost completely abstaining from alcohol, opting for water instead. Their alcohol consumption became negligible, suggesting that gene therapy might offer a lasting solution for those suffering from severe AUD.
This revelation offers a beacon of hope for many. According to the National Institute on Alcohol Abuse and Alcoholism, 29.5 million individuals were diagnosed with AUD in the US in 2021, including nearly a million young individuals between the ages of 12 and 17.
While these initial findings are promising, extensive research and trials are necessary to determine if this gene therapy can be effectively and safely applied to humans. Nevertheless, this pioneering study stands as a testament to human perseverance and scientific pursuit. We may be on the verge of a solution that provides relief and healing to millions.
If future research confirms these findings in humans, this groundbreaking treatment could save countless lives and restore hope to those struggling with alcohol addiction. This innovative approach exemplifies the power of scientific research and the relentless quest to find solutions to humanity’s most challenging health issues.